Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | $40,278,000 | $34,665,000 | $44,753,000 | $35,797,000 |
| % Growth | 16.2% | -22.5% | 25% | – |
| Cost of Goods Sold | $15,472,000 | $13,379,000 | $19,945,000 | $13,818,000 |
| Gross Profit | $24,806,000 | $21,286,000 | $24,808,000 | $21,979,000 |
| % Margin | 61.6% | 61.4% | 55.4% | 61.4% |
| R&D Expenses | $0 | $0 | $10,903,000 | $0 |
| G&A Expenses | $0 | $0 | -$26,641,000 | $0 |
| SG&A Expenses | $20,043,000 | $17,920,000 | $19,133,000 | $17,765,000 |
| Sales & Mktg Exp. | $0 | $0 | $34,871,000 | $0 |
| Other Operating Expenses | -$1,000 | $2,000 | -$10,903,000 | $0 |
| Operating Expenses | $20,042,000 | $17,922,000 | $19,133,000 | $17,765,000 |
| Operating Income | $4,764,000 | $3,364,000 | $5,675,000 | $4,214,000 |
| % Margin | 11.8% | 9.7% | 12.7% | 11.8% |
| Other Income/Exp. Net | $1,478,000 | $427,000 | $3,600,000 | $2,096,000 |
| Pre-Tax Income | $6,242,000 | $3,791,000 | $9,275,000 | $6,310,000 |
| Tax Expense | $1,652,000 | $1,154,000 | $1,035,000 | $1,650,000 |
| Net Income | $4,458,000 | $2,564,000 | $8,098,000 | $4,562,000 |
| % Margin | 11.1% | 7.4% | 18.1% | 12.7% |
| EPS | 62.08 | 35.13 | 111 | 62.32 |
| % Growth | 76.7% | -68.4% | 78.1% | – |
| EPS Diluted | 61.99 | 35.1 | 110.82 | 62.22 |
| Weighted Avg Shares Out | 71,914 | 73,048 | 73,072 | 73,323 |
| Weighted Avg Shares Out Dil | 71,914 | 73,048 | 73,071 | 73,323 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $597,000 | $991,000 | $886,000 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,748,500 | -$3,366,000 | $1,583,750 | $1,494,500 |
| EBITDA | $6,511,500 | $0 | $7,258,750 | $5,708,500 |
| % Margin | 16.2% | 0% | 16.2% | 15.9% |